Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

ESMO open

Showing results (11-20 of 2,231) with videos related to

Pageof 224
Sort By:
ESMO Open|November 16, 2018
Biosimilars in oncologyJosep Tabernero
ESMO Open|July 30, 2019
Educational needs in gastrointestinal cancer: a consensus position paper from the ESMO Gastrointestinal Cancer FacultyFlorian Lordick, Radka Obermannova, Doris Vola, et al.
ESMO Open|January 15, 2021
Flexible care in breast cancerA Wardley, J-L Canon, L Elsten, et al.
ESMO Open|January 15, 2021
First-line immune checkpoint inhibitors for extensive stage small-cell lung cancer: clinical developments and future directionsA Ortega-Franco, C Ackermann, L Paz-Ares, et al.
ESMO Open|January 19, 2021
Molecular predictors of EGFR-mutant NSCLC transformation into LCNEC after frontline osimertinib: digging under the surfaceL Belluomini, A Caliò, R Giovannetti, et al.
ESMO Open|August 28, 2020
Oncological care organisation during COVID-19 outbreakConcetta Elisa Onesti, Hope S Rugo, Daniele Generali, et al.
ESMO Open|August 28, 2020
Combinations in the first-line treatment of patients with advanced/metastatic renal cell cancer: regulatory aspectsLuca Moscetti, Paula Hennik, Bjorg Bolstad, et al.
ESMO Open|August 28, 2020
Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trialRobin Kate Kelley, Baek-Yeol Ryoo, Philippe Merle, et al.
ESMO Open|January 14, 2021
Poly(ADP-ribose) polymerase inhibitor-associated myelodysplastic syndrome/acute myeloid leukemia: a pharmacovigilance analysis of the FAERS databaseZ Ma, X M Sun, W C Lu, et al.
ESMO Open|February 4, 2021
Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor BoardsR Danesi, S Fogli, S Indraccolo, et al.
Pageof 224

Showing results (11-20 of 2,231) with videos related to

Sort By:
Pageof 224
ESMO Open|November 16, 2018
Biosimilars in oncologyJosep Tabernero
ESMO Open|July 30, 2019
Educational needs in gastrointestinal cancer: a consensus position paper from the ESMO Gastrointestinal Cancer FacultyFlorian Lordick, Radka Obermannova, Doris Vola, et al.
ESMO Open|January 15, 2021
Flexible care in breast cancerA Wardley, J-L Canon, L Elsten, et al.
ESMO Open|January 15, 2021
First-line immune checkpoint inhibitors for extensive stage small-cell lung cancer: clinical developments and future directionsA Ortega-Franco, C Ackermann, L Paz-Ares, et al.
ESMO Open|January 19, 2021
Molecular predictors of EGFR-mutant NSCLC transformation into LCNEC after frontline osimertinib: digging under the surfaceL Belluomini, A Caliò, R Giovannetti, et al.
ESMO Open|August 28, 2020
Oncological care organisation during COVID-19 outbreakConcetta Elisa Onesti, Hope S Rugo, Daniele Generali, et al.
ESMO Open|August 28, 2020
Combinations in the first-line treatment of patients with advanced/metastatic renal cell cancer: regulatory aspectsLuca Moscetti, Paula Hennik, Bjorg Bolstad, et al.
ESMO Open|August 28, 2020
Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trialRobin Kate Kelley, Baek-Yeol Ryoo, Philippe Merle, et al.
ESMO Open|January 14, 2021
Poly(ADP-ribose) polymerase inhibitor-associated myelodysplastic syndrome/acute myeloid leukemia: a pharmacovigilance analysis of the FAERS databaseZ Ma, X M Sun, W C Lu, et al.
ESMO Open|February 4, 2021
Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor BoardsR Danesi, S Fogli, S Indraccolo, et al.
Pageof 224